Tango Therapeutics, Inc.

TNGX

$24.45

Updated: 23/09/2026, 22:09:26

Market Cap

$3.98B

Sector

Healthcare

Industry

Biotechnology

Country

Stock valuation chart

One-year closing share-price history for TNGX

Company Profile

Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5). This compound is currently being advanced as a potential therapy for cancers characterized by methylthioadenosine phosphorylase (MTAP) deletions. Additionally, their pipeline includes an Ubiquitin-specific protease 1 (USP1) inhibitor targeting BRCA1 or BRCA2-mutant cancers, and a program known as 'Target 3' which addresses STK11-mutant cancers. Tango Therapeutics maintains a strategic alliance with Gilead Sciences, Inc., focused on the identification, advancement, and commercialization of a diverse array of cancer therapies. Established in 2017, the company's operations are headquartered in Cambridge, Massachusetts.

USD

NASDAQ

CEO: Malte Peters

Employees: 137

https://www.tangotx.com

Asset Summaries

Latest generated summaries for TNGX

No summaries found.

Detailed business

Structured knowledge from the latest official annual filing.

No official annual filing has completed ingestion for this company yet. The filing worker processes major-index companies incrementally and never repeats a completed fiscal year.

Full company information

Latest profile, trading, valuation, and identifier data stored for TNGX.

Share price: $24.45
Market cap: $3.98B
Exchange: NASDAQ
Currency: USD
CEO: Malte Peters
Employees: 137
IPO date: 03/09/2020
Beta: 1.12
Last dividend: $0.00
Day range: $24.06 – $25.92
52-week range: $6.69 – $34.39
1-day performance: -4.23%
1-year performance: 265.47%
Current drawdown (1Y): -28.90%
CIK: 0001819133
CUSIP: 87583X109
ISIN: US87583X1090
Created: 07/12/2025, 14:36:22
Last update: 23/09/2026, 22:09:26

Track Tango Therapeutics, Inc. with an AI analyst

See which prediction-market events move TNGX, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.

Create a free account See what the world decides next

Free forever to follow AlphaBrain’s AI strategies. No card required.

Latest Database News

News linked to TNGX from your Railway `news_articles` table.

Tango Therapeutics Announces Pricing of $600 Million Upsized Public Offering

GlobeNewsWire • STOCK • 10/06/2026, 00:49:00

Tango Therapeutics (NASDAQ:TNGX) Surges on Promising Pancreatic Cancer Trial Results and Analyst Price Target Hike

Market Data • Market Data • 08/06/2026, 20:08:44

Tango Therapeutics, Inc. (TNGX) Discusses Promising Clinical Results for Vopimetostat and Pan-RAS Inhibitor Combination in MTAP-Deleted Pancreatic Cancer Transcript

Seeking Alpha • STOCK • 08/06/2026, 18:28:31

Tango Therapeutics (NASDAQ: TNGX) Stock Soars on Positive Pancreatic Cancer Trial Results and Upgrade

Market Data • Market Data • 08/06/2026, 18:09:18

Tango Therapeutics Announces Proposed $500 Million Public Offering

GlobeNewsWire • STOCK • 08/06/2026, 18:01:00

Tango Therapeutics Stock Soars 42% After 'Unprecedented' Data on Pancreatic Cancer Treatment

Barrons • STOCK • 08/06/2026, 14:28:00

Tango Therapeutics' pancreatic cancer drug combo shows promise in study

Reuters • STOCK • 08/06/2026, 10:15:45

Tango Therapeutics Announces Leadership Appointments to Accelerate Late-Stage Development of Vopimetostat

GlobeNewsWire • STOCK • 15/04/2026, 11:05:00

Avoro Capital Advisors LLC Takes $4.58 Million Position in Tango Therapeutics, Inc. $TNGX

Defense World • STOCK • 14/03/2026, 04:07:16

Tango Therapeutics: I'm Not Buying Into Latest Rally, Despite PRMT5 Promise

Seeking Alpha • STOCK • 06/03/2026, 17:02:05